Misregulation of PPAR functioning and its pathogenic consequences associated with nonalcoholic fatty liver disease in human obesity

PPAR Research

Volumn , Issue , 2012, Pages

  Videla, Luis A ^a   Pettinelli, Paulina ^b  

^a UNIVERSITY OF CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FATTY ACID; FIBRIC ACID DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; POLYUNSATURATED FATTY ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR AP 1; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE COURSE; DNA BINDING; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; FATTY ACID OXIDATION; FATTY LIVER; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HYPOADIPONECTINEMIA; INSULIN RESISTANCE; LIPOGENESIS; LIVER CELL; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN GLYCOSYLATION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SCORING SYSTEM; SIGNAL TRANSDUCTION; STEATOSIS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84872151568     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2012/107434     Document Type: Article

References (152)

1. Charlton M. R., Burns J. M., Pedersen R. A., Watt K. D., Heimbach J. K., Dierkhising R. A., Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011 141 4 1249 1253
2. Byrne C. D., Non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabetic Medicine 2012 29 9 1098 1107. Dorothy Hodgkin Lecture 2012
3. Videla L. A., Rodrigo R., Araya J., Poniachik J., Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends in Molecular Medicine 2006 12 12 555 558 2-s2.0-33751193496 10.1016/j.molmed.2006. 10.001 (Pubitemid 44780196)
4. Saadeh S., Younossi Z. M., Remer E. M., Gramlich T., Ong J. P., Hurley M., Mullen K. D., Cooper J. N., Sheridan M. J., The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002 123 3 745 750 2-s2.0-0036729447 10.1053/gast.2002.35354 (Pubitemid 34977081)
5. Fracanzani A. L., Valenti L., Bugianesi E., Andreoletti M., Colli A., Vanni E., Bertelli C., Fatta E., Bignamini D., Marchesini G., Fargion S., Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008 48 3 792 798 2-s2.0-51349083814 10.1002/hep.22429
6. Browning J. D., Szczepaniak L. S., Dobbins R., Nuremberg P., Horton J. D., Cohen J. C., Grundy S. M., Hobbs H. H., Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004 40 6 1387 1395 2-s2.0-10644220306 10.1002/hep.20466 (Pubitemid 39657013)
7. Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G., A position statement on NAFLD/NASH based on the EASL 2009 special conference. Journal of Hepatology 2010 53 2 372 384 2-s2.0-77952529040 10.1016/j.jhep.2010. 04.008
8. Schwimmer J. B., Deutsch R., Kahen T., Lavine J. E., Stanley C., Behling C., Prevalence of fatty liver in children and adolescents. Pediatrics 2006 118 4 1388 1393 2-s2.0-33750002388 10.1542/peds.2006-1212 (Pubitemid 46393782)
9. Stienstra R., Duval C., Müller M., Kersten S., PPARs, obesity, and inflammation. PPAR Research 2007 2007 10 2-s2.0-42749103304 10.1155/2007/95974 95974
10. Kotronen A., Seppälä-Lindroos A., Bergholm R., Yki-Järvinen H., Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome. Diabetologia 2008 51 1 130 138 2-s2.0-36649027452 10.1007/s00125-007- 0867-x (Pubitemid 50003448)
11. Musso G., Gambino R., Cassader M., Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Progress in Lipid Research 2009 48 1 1 26 2-s2.0-57649214103 10.1016/j.plipres.2008.08.001
12. Donnelly K. L., Smith C. I., Schwarzenberg S. J., Jessurun J., Boldt M. D., Parks E. J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. Journal of Clinical Investigation 2005 115 5 1343 1351 2-s2.0-18244382304 10.1172/JCI200523621 (Pubitemid 40629054)
13. Aronis A., Madar Z., Tirosh O., Mechanism underlying oxidative stress-mediated lipotoxicity: exposure of J774.2 macrophages to triacylglycerols facilitates mitochondrial reactive oxygen species production and cellular necrosis. Free Radical Biology and Medicine 2005 38 9 1221 1230 2-s2.0-15944425804 10.1016/j.freeradbiomed.2005.01.015 (Pubitemid 40445539)
14. Bensinger S. J., Tontonoz P., Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008 454 7203 470 477 2-s2.0-47949094965 10.1038/nature07202
15. Berger J. P., Akiyama T. E., Meinke P. T., PPARs: therapeutic targets for metabolic disease. Trends in Pharmacological Sciences 2005 26 5 244 251 2-s2.0-18044376795 10.1016/j.tips.2005.03.003 (Pubitemid 40603072)
16. Michalik L., Auwerx J., Berger J. P., Chatterjee V. K., Glass C. K., Gonzalez F. J., Grimaldi P. A., Kadowaki T., Lazar M. A., O'Rahilly S., Palmer C. N. A., Plutzky J., Reddy J. K., Spiegelman B. M., Staels B., Wahli W., International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacological Reviews 2006 58 4 726 741 2-s2.0-33751533892 10.1124/pr.58.4.5 (Pubitemid 44833742)
17. Lazar M. A., PPAR γ 10 years later. Biochimie 2005 87 1 9 13 2-s2.0-14544303179 10.1016/j.biochi.2004.10.021 (Pubitemid 40298759)
18. Batista F. A., Trivella D. B., Bernardes A., Gratieri J., Oliveira P. S., Figueira A. C., Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding. PLoS One 2012 7 5 e33643
19. Desvergne B., Wahli W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 1999 20 5 649 688 2-s2.0-0033305213 (Pubitemid 30650602)
20. Kersten S., Desvergne B., Wahli W., Roles of PPARS in health and disease. Nature 2000 405 6785 421 424 2-s2.0-0034713444 10.1038/35013000 (Pubitemid 30367411)
21. Rakhshandehroo M., Knoch B., Müller M., Kersten S., Peroxisome proliferator-activated receptor alpha target genes. PPAR Research 2010 2010 20 2-s2.0-78349283454 10.1155/2010/612089 612089
22. Palmer C. N. A., Hsu M. H., Griffin K. J., Raucy J. L., Johnson E. F., Peroxisome proliferator activated receptor- α expression in human liver. Molecular Pharmacology 1998 53 1 14 22 2-s2.0-0031952238 (Pubitemid 28068368)
23. Rakhshandehroo M., Hooiveld G., Müller M., Kersten S., Comparative analysis of gene regulation by the transcription factor PPAR α between mouse and human. PLoS ONE 2009 4 8 2-s2.0-69449086702 10.1371/journal.pone. 0006796 e6796
24. Gervois P., Pineda Torra I., Chinetti G., Grötzinger T., Dubois G., Fruchart J. C., Fruchart-Najib J., Leitersdorf E., Staels B., A truncated human peroxisome proliferator-activated receptor α splice variant with dominant negative activity. Molecular Endocrinology 1999 13 9 1535 1549 2-s2.0-0033304779 (Pubitemid 30650594)
25. Chen S., Li Y., Li S., Yu C., A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio. Journal of Gastroenterology and Hepatology 2008 23 9 1415 1418 2-s2.0-49849093922 10.1111/j.1440-1746.2008.05523.x
26. Dongiovanni P., Rametta R., Fracanzani A. L., Benedan L., Borroni V., Maggioni P., Maggioni M., Fargion S., Valenti L., Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study. BMC Gastroenterology 2010 10, article 102 2-s2.0-77956461321 10.1186/1471-230X-10-102
27. Schoonjans K., Staels B., Auwerx J., Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. Journal of Lipid Research 1996 37 5 907 925 2-s2.0-0029994543 (Pubitemid 26182326)
28. Kliewer S. A., Sundseth S. S., Jones S. A., Brown P. J., Wisely G. B., Koble C. S., Devchand P., Wahli W., Willson T. M., Lenhard J. M., Lehmann J. M., Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ Proceedings of the National Academy of Sciences of the United States of America 1997 94 9 4318 4323 2-s2.0-0006132932 10.1073/pnas.94.9.4318 (Pubitemid 27194239)
29. Luquet S., Lopez-Soriano J., Holst D., Gaudel C., Jehl-Pietri C., Fredenrich A., Grimaldi P. A., Roles of peroxisome proliferator-activated receptor delta (PPAR δ) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Biochimie 2004 86 11 833 837 2-s2.0-10044224688 10.1016/j.biochi.2004.09.024 (Pubitemid 39602763)
30. Dubuquoy L., Dharancy S., Nutten S., Pettersson S., Auwerx J., Desreumaux P., Role of peroxisome proliferator-activated receptor γ and retinoid X receptor heterodimer in hepatogastroenterological diseases. The Lancet 2002 360 9343 1410 1418 2-s2.0-0037010478 10.1016/S0140-6736(02)11395-X (Pubitemid 35341309)
31. Damiano F., Gnoni G. V., Siculella L., Citrate carrier promoter is target of peroxisome proliferator-activated receptor alpha and gamma in hepatocytes and adipocytes. International Journal of Biochemistry & Cell Biology 2012 44 4 659 668
32. Wang Y., Lam K. S. L., Yau M. H., Xu A., Post-translational modifications of adiponectin: mechanisms and functional implications. Biochemical Journal 2008 409 3 623 633 2-s2.0-38949125405 10.1042/BJ20071492 (Pubitemid 351214189)
33. Tailleux A., Wouters K., Staels B., Roles of PPARs in NAFLD: potential therapeutic targets. Biochimica Et Biophysica Acta 2012 1821 5 809 818
34. Wang Y. X., PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Research 2010 20 2 124 137 2-s2.0-76449100708 10.1038/cr.2010.13
35. Vidal-Puig A. J., Considine R. V., Jimenez-Liñan M., Werman A., Pories W. J., Caro J. F., Flier J. S., Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. Journal of Clinical Investigation 1997 99 10 2416 2422 2-s2.0-0030977450 (Pubitemid 27227719)
36. Kim K. H., Hong S. P., Kim K., Park M. J., Kim K. J., Cheong J., HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPAR γ Biochemical and Biophysical Research Communications 2007 355 4 883 888 2-s2.0-33847633412 10.1016/j.bbrc.2007.02.044 (Pubitemid 46366910)
37. Kim K. H., Shin H. J., Kim K., Choi H. M., Rhee S. H., Moon H. B., Kim H. H., Yang U. S., Yu D. Y., Cheong J., Hepatitis B Virus X Protein Induces Hepatic Steatosis Via Transcriptional Activation of SREBP1 and PPAR γ Gastroenterology 2007 132 5 1955 1967 2-s2.0-34247637220 10.1053/j.gastro.2007. 03.039 (Pubitemid 46677949)
38. Kim K., Kim K. H., Ha E., Park J. Y., Sakamoto N., Cheong J., Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. FEBS Letters 2009 583 17 2720 2726 2-s2.0-69249229453 10.1016/j.febslet.2009.07.034
39. Gawrieh S., Marion M. C., Komorowski R., Wallace J., Charlton M., Kissebah A., Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Digestive Diseases and Sciences 2012 57 4 952 957
40. Yang Z., Wen J., Li Q., Tao X., Ye Z., He M., PPARG gene Pro12Ala variant contributes to the development of non-alcoholic fatty liver in middle-aged and older Chinese population. Molecular and Cellular Endocrinology 2012 348 1 255 259 10.1016/j.mce.2011.09.001
41. Deeb S. S., Fajas L., Nemoto M., Pihlajamaki J., Mykkanen L., Kuusisto J., Laakso M., Fujimoto W., Auwerx J., A Pro12Ala substitution in PPAR γ 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature Genetics 1998 20 3 284 287 2-s2.0-0031595923 10.1038/3099 (Pubitemid 28507675)
42. Altshuler D., Hirschhorn J. N., Klannemark M., Lindgren C. M., Vohl M. C., Nemesh J., Lane C. R., Schaffner S. F., Bolk S., Brewer C., Tuomi T., Gaudet D., Hudson T. J., Daly M., Groop L., Lander E. S., The common PPAR γ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genetics 2000 26 1 76 80 2-s2.0-0033624575 10.1038/79216
43. Doney A. S. F., Fischer B., Cecil J. E., Boylan K., McGuigan F. E., Ralston S. H., Morris A. D., Palmer C. N. A., Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes. Diabetologia 2004 47 3 555 558 2-s2.0-1842866370 10.1007/s00125-003- 1323-1 (Pubitemid 38491254)
44. Oliver W. R., Shenk J. L., Snaith M. R., Russell C. S., Plunket K. D., Bodkin N. L., Lewis M. C., Winegar D. A., Sznaidman M. L., Lambert M. H., Xu H. E., Sternbach D. D., Kliewer S. A., Hansen B. C., Willson T. M., A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proceedings of the National Academy of Sciences of the United States of America 2001 98 9 5306 5311 2-s2.0-0035942162 10.1073/pnas.091021198 (Pubitemid 32397124)
45. Liu S., Hatano B., Zhao M., Yen C. C., Kang K., Reilly S. M., Gangl M. R., Gorgun C., Balschi J. A., Ntambi J. M., Lee C. H., Role of peroxisome proliferator-activated receptor δ / β in hepatic metabolic regulation. Journal of Biological Chemistry 2011 286 2 1237 1247 2-s2.0-78651384181 10.1074/jbc.M110.138115
46. Risérus U., Sprecher D., Johnson T., Olson E., Hirschberg S., Liu A., Fang Z., Hegde P., Richards D., Sarov-Blat L., Strum J. C., Basu S., Cheeseman J., Fielding B. A., Humphreys S. M., Danoff T., Moore N. R., Murgatroyd P., O'Rahilly S., Sutton P., Willson T., Hassall D., Frayn K. N., Karpe F., Activation of peroxisome proliferator-activated receptor (PPAR) δ promotes reversal of multiple metabolic abnormalities, Reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 2008 57 2 332 339 2-s2.0-39649101196 10.2337/db07-1318
47. Ooi E. M., Watts G. F., Sprecher D. L., Chan D. C., Barrett P. H., Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. Journal of Clinical Endocrinology & Metabolism 2011 96 10 1568 1576
48. Bays H. E., Schwartz S., Littlejohn III T., Kerzner B., Krauss R. M., Karpf D. B., MBX-8025, a novel peroxisome proliferator receptor delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. Journal of Clinical Endocrinology & Metabolism 2011 96 9 2889 2289
49. Choi Y. J., Roberts B. K., Wang X., Geaney J. C., Naim S., Wojnoonski K K., Effects ofthe PPAR- σ agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis 2012 220 2 470 476
50. Serrano-Marco L., Chacón M. R., Maymó-Masip E., Barroso E., Salvadó L., Wabistch M., TNF- α inhibits PPAR β / σ activity and SIRT1 expression through NF- B in human adipocytes. Biochimica Et Biophysica Acta 2012 1821 9 1177 1185
51. Araya J., Rodrigo R., Videla L. A., Thielemann L., Orellana M., Pettinelli P., Poniachik J., Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clinical Science 2004 106 6 635 643 2-s2.0-2942706241 10.1042/CS20030326 (Pubitemid 38797577)
52. Kashi M. R., Torres D. M., Harrison S. A., Current and emerging therapies in nonalcoholic fatty liver disease. Seminars in Liver Disease 2008 28 4 396 406 2-s2.0-56649117397 10.1055/s-0028-1091984
53. George J., Liddle C., Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Molecular Pharmaceutics 2008 5 1 49 59 2-s2.0-39649096642 10.1021/mp700110z (Pubitemid 351300034)
54. Gawrieh S., Opara E. C., Koch T. R., Oxidative stress in nonalcoholic fatty liver disease: pathogenesis and antioxidant therapies. Journal of Investigative Medicine 2004 52 8 506 514 2-s2.0-12144284997 (Pubitemid 40105592)
55. Sies H., Stahl W., Sevanian A., Nutritional, dietary and postprandial oxidative stress. Journal of Nutrition 2005 135 5 96 972 2-s2.0-18344385579 (Pubitemid 40638292)
56. McGarry J. D., Foster D. W., Regulation of hepatic fatty acid oxidation and ketone body production. Annual Review of Biochemistry 1980 49 395 420 2-s2.0-0018864840
57. Videla L. A., Rodrigo R., Orellana M., Fernandez V., Tapia G., Quiñones L., Varela N., Contreras J., Lazarte R., Csendes A., Rojas J., Maluenda F., Burdiles P., Diaz J. C., Smok G., Thielemann L., Poniachik J., Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clinical Science 2004 106 3 261 268 2-s2.0-12144291550 10.1042/CS20030285 (Pubitemid 38365832)
58. Malaguarnera L., Madeddu R., Palio E., Arena N., Malaguarnera M., Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. Journal of Hepatology 2005 42 4 585 591 2-s2.0-14844288046 10.1016/j.jhep.2004.11.040 (Pubitemid 40342940)
59. Oliveira C. P. M. S., Faintuch J., Rascovski A., Furuya C. K., Do Socorro Bastos M., Matsuda M., Della Nina B. I., Yahnosi K., Abdala D. S. P., Vezozzo D. C. P., Alves V. A. F., Zilberstein B., Garrido A. B., Halpern A., Carrilho F. J., Gama-Rodrigues J. J., Lipid peroxidation in bariatric candidates with nonalcoholic fatty liver disease (NAFLD)-preliminary findings. Obesity Surgery 2005 15 4 502 505 2-s2.0-18044366549 10.1381/0960892053723493 (Pubitemid 40605073)
60. Sanyal A. J., Campbell-Sargent C., Mirshahi F., Rizzo W. B., Contos M. J., Sterling R. K., Luketic V. A., Shiffman M. L., Clore J. N., Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001 120 5 1183 1192 2-s2.0-0035084699 (Pubitemid 32246672)
61. Malaguarnera L., Di Rosa M., Zambito A. M., Dell'Ombra N., Nicoletti F., Malaguarnera M., Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. Gut 2006 55 9 1313 1320 2-s2.0-33747751924 10.1136/gut.2005.075697 (Pubitemid 44277364)
62. Loguercio C., De Girolamo V., De Sio I., Tuccillo C., Ascione A., Baldi F., Budillon G., Cimino L., Di Carlo A., Pia Di Marino M., Morisco F., Picciotto F., Terracciano L., Vecchione R., Verde V., Del Vecchio Blanco C., Non-alcoholic fatty liver disease in an area of southern italy: main clinical, histological, and pathophysiological aspects. Journal of Hepatology 2001 35 5 568 574 2-s2.0-0035164629 10.1016/S0168-8278(01)00192-1 (Pubitemid 33078265)
63. Evans J. L., Maddux B. A., Goldfine I. D., The molecular basis for oxidative stress-induced insulin resistance. Antioxidants and Redox Signaling 2005 7 7-8 1040 1052 2-s2.0-22044443268 10.1089/ars.2005.7.1040 (Pubitemid 40967154)
64. Houstis N., Rosen E. D., Lander E. S., Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006 440 7086 944 948 2-s2.0-33645860825 10.1038/nature04634
65. Yu C., Chen Y., Cline G. W., Zhang D., Zong H., Wang Y., Bergeron R., Kim J. K., Cushman S. W., Cooney G. J., Atcheson B., White M. F., Kraegen E. W., Shulman G. I., Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. Journal of Biological Chemistry 2002 277 52 50230 50236 2-s2.0-0037184925 10.1074/jbc.M200958200 (Pubitemid 36042170)
66. Neschen S., Morino K., Hammond L. E., Zhang D., Liu Z. X., Romanelli A. J., Cline G. W., Pongratz R. L., Zhang X. M., Choi C. S., Coleman R. A., Shulman G. I., Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell Metabolism 2005 2 1 55 65 2-s2.0-27244440736 10.1016/j.cmet.2005.06.006 (Pubitemid 43239825)
67. Sies H., Biochemistry of oxidative stress. Angewandte Chemie 1986 25 1058 1071
68. Witting L. A., Lipid peroxidation in vivo. Journal of the American Oil Chemists Society 1965 42 11 908 913 2-s2.0-0013816732 10.1007/BF02632443
69. Elizondo A., Araya J., Rodrigo R., Poniachik J., Csendes A., Maluenda F., Díaz J. C., Signorini C., Sgherri C., Comportai M., Videla L. A., Polyunsaturated fatty acid pattern in liver and erythrocyte phospholipids from obese patients. Obesity 2007 15 1 24 31 2-s2.0-33846868166 10.1038/oby.2007.518 (Pubitemid 46219780)
70. Pettinelli P., del Pozo T., Araya J., Rodrigo R., Araya A. V., Smok G., Csendes A., Gutierrez L., Rojas J., Korn O., Maluenda F., Diaz J. C., Rencoret G., Braghetto I., Castillo J., Poniachik J., Videla L. A., Enhancement in liver SREBP-1c/PPAR- α ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochimica et Biophysica Acta 2009 1792 11 1080 1086 2-s2.0-73349125811 10.1016/j.bbadis.2009.08.015
71. Elizondo A., Araya J., Rodrigo R., Signorini C., Sgherri C., Comporti M., Poniachik J., Videla L. A., Effects of weight loss on liver and erythrocyte polyunsaturated fatty acid pattern and oxidative stress status in obese patients with non-alcoholic fatty liver disease. Biological Research 2008 41 1 59 68 2-s2.0-51449107605
72. Videla L. A., Rodrigo R., Araya J., Poniachik J., Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radical Biology and Medicine 2004 37 9 1499 1507 2-s2.0-5344239586 10.1016/j.freeradbiomed.2004.06.033 (Pubitemid 39349251)
73. Gao L., Wang J., Sekhar K. R., Yin H., Yared N. F., Schneider S. N., Sasi S., Dalton T. P., Anderson M. E., Chan J. Y., Morrow J. D., Freeman M. L., Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. Journal of Biological Chemistry 2007 282 4 2529 2537 2-s2.0-34047273206 10.1074/jbc.M607622200 (Pubitemid 47076775)
74. Fernández V., Tapia G., Videla L. A., Recent advances in liver preconditioning: thyroid hormone, n-3 long-chain polyunsaturated fatty acids and iron. World Journal of Hepatology 2012 4 4 119 128
75. Araya J., Rodrigo R., Pettinelli P., Araya A. V., Poniachik J., Videla L. A., Decreased liver fatty Acid δ -6 and δ -5 desaturase activity in obese patients. Obesity 2010 18 7 1460 1463 2-s2.0-77954143472 10.1038/oby.2009.379
76. Nakamura M. T., Nara T. Y., Structure, function, and dietary regulation of Δ6, Δ5, and Δ9 desaturases. Annual Review of Nutrition 2004 24 345 376 2-s2.0-3142753961 10.1146/annurev.nutr.24.121803.063211 (Pubitemid 38938796)
77. Gormaz J. G., Rodrigo R., Videla L. A., Beems M., Biosynthesis and bioavailability of long-chain polyunsaturated fatty acids in non-alcoholic fatty liver disease. Progress in Lipid Research 2010 49 4 407 419 2-s2.0-77956394810 10.1016/j.plipres.2010.05.003
78. Baylin A., Kabagambe E. K., Siles X., Campos H., Adipose tissue biomarkers of fatty acid intake. American Journal of Clinical Nutrition 2002 76 4 750 757 2-s2.0-0036784099
79. Clarke S. D., Nonalcoholic Steatosis and Steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription. American Journal of Physiology 2001 281 4 G865 G869 2-s2.0-0034791616
80. Jump D. B., Botolin D., Wang Y., Xu J., Christian B., Demeure O., Fatty acid regulation of hepatic gene transcription. Journal of Nutrition 2005 135 11 2503 2506 2-s2.0-31544455792 (Pubitemid 43156586)
81. Lombardo Y. B., Chicco A. G., Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. Journal of Nutritional Biochemistry 2006 17 1 1 13 2-s2.0-28844485678 10.1016/j.jnutbio.2005.08.002 (Pubitemid 41774400)
82. Charlton M., Sreekumar R., Rasmussen D., Lindor K., Nair K. S., Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002 35 4 898 904 2-s2.0-0036207720 10.1053/jhep.2002.32527 (Pubitemid 34258385)
83. Meunier-Durmort C., Poirier H., Niot I., Forest C., Besnard P., Up-regulation of the expression of the gene for liver fatty acid-binding protein by long-chain fatty acids. Biochemical Journal 1996 319 2 483 487 2-s2.0-0029830285 (Pubitemid 26372207)
84. Carlsson L., Lindén D., Jalouli M., Oscarsson J., Effects of fatty acids and growth hormone on liver fatty acid binding protein and PPAR α in rat liver. American Journal of Physiology 2001 281 4 E772 E781 2-s2.0-0034779607
85. Valenzuela R., Videla L. A., The importance of the long-chain polyunsaturated fatty acid n-6/n-3 ratio in development of non-alcoholic fatty liver associated with obesity. Food and Function 2011 2 11 644 648
86. Pacchikian B. D., Essaghir A., Demoulin J. B., Hepatic n-3 polyunsaturated fatty acid depletion promotes steatosis and insulin resistance in mice: genomic analysis of cellular targets. PLos ONE 2011 6 8 e23365 10.1371/journal.pone.0023365
87. Pagano C., Soardo G., Esposito W., Fallo F., Basan L., Donnini D., Federspil G., Sechi L. A., Vettor R., Plasma adiponectin is decreased in nonalcoholic fatty liver disease. European Journal of Endocrinology 2005 152 1 113 118 2-s2.0-13244295710 10.1530/eje.1.01821 (Pubitemid 40185459)
88. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J. I., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., Muraguchi M., Ohmoto Y., Funahashi T., Matsuzawa Y., Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communications 1999 257 1 79 83 2-s2.0-0033515761 10.1006/bbrc.1999.0255 (Pubitemid 29299050)
89. Czaja M. J., Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology 2004 40 1 19 22 2-s2.0-3042820278 10.1002/hep.20328 (Pubitemid 38868918)
90. Kadowaki T., Yamauchi T., Kubota N., The physiological and pathophysiological role of adiponectin and adiponectin receptors in the peripheral tissues and CNS. FEBS Letters 2008 582 1 74 80 2-s2.0-37549040190 10.1016/j.febslet.2007.11.070 (Pubitemid 50012818)
91. Mao X., Kikani C. K., Riojas R. A., Langlais P., Wang L., Ramos F. J., Fang Q., Christ-Roberts C. Y., Hong J. Y., Kim R. Y., Liu F., Dong L. Q., APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nature Cell Biology 2006 8 5 516 523 2-s2.0-33744972277
92. Yoon M. J., Lee G. Y., Chung J. J., Ahn Y.-H., Hong S. H., Kim J. B., Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor α Diabetes 2006 55 9 2562 2570 2-s2.0-33750578279 10.2337/db05-1322 (Pubitemid 44871157)
93. Barger P. M., Browning A. C., Garner A. N., Kelly D. P., p38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor α: a potential role in the cardiac metabolic stress response. Journal of Biological Chemistry 2001 276 48 44495 44501 2-s2.0-0035977050 10.1074/jbc.M105945200
94. Pettinelli P., Videla L. A., Up-regulation of PPAR- γ mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. Journal of Clinical Endocrinology and Metabolism 2011 96 5 1424 1430 2-s2.0-79955650290 10.1210/jc.2010-2129
95. Kaser S., Maschen A., Cayon A., Kaser A., Crespo J., Pons-Romero F., Ebenbichler C. F., Patsch J. R., Tilg H., Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005 54 1 117 121 2-s2.0-10844220730 10.1136/gut.2003.037010 (Pubitemid 40007229)
96. Neher M. D., Weckbach S., Huber-Lang M. S., Stahel P. F., New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury. PPAR Research 2012 2012 13 728461 10.1155/2012/728461
97. Kallwitz E. R., McLachlan A., Cotler S. J., Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World Journal of Gastroenterology 2008 14 1 22 28 2-s2.0-39849099238 10.3748/wjg.14.22 (Pubitemid 351314322)
98. Boelsterli U. A., Bedoucha M., Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPAR γ) expression in the liver: insights from models of obesity and type 2 diabetes. Biochemical Pharmacology 2002 63 1 1 10 2-s2.0-0036145372 10.1016/S0006-2952(01)00817-6 (Pubitemid 34075287)
99. Greco D., Kotronen A., Westerbacka J., Puig O., Arkkila P., Kiviluoto T., Laitinen S., Kolak M., Fisher R. M., Hamsten A., Auvinen P., Yki-Järvinen H., Gene expression in human NAFLD. American Journal of Physiology 2008 294 5 G1281 G1287 2-s2.0-45849118669 10.1152/ajpgi.00074.2008
100. Westerbacka J., Kolak M., Kiviluoto T., Arkkila P., Sirén J., Hamsten A., Fisher R. M., Yki-Järvinen H., Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 2007 56 11 2759 2765 2-s2.0-35748972366 10.2337/db07-0156 (Pubitemid 350044919)
101. Marfella R., Di Filippo C., Portoghese M., Barbieri M., Ferraraccio F., Siniscalchi M., Cacciapuoti F., Rossi F., D'Amico M., Paolisso G., Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome. Journal of Lipid Research 2009 50 11 2314 2323 2-s2.0-70350349875 10.1194/jlr.P900032-JLR200
102. Nielsen S., Guo Z., Johnson C. M., Hensrud D. D., Jensen M. D., Splanchnic lipolysis in human obesity. Journal of Clinical Investigation 2004 113 11 1582 1588 2-s2.0-2942726508 10.1172/JCI200421047 (Pubitemid 39071681)
103. Fabbrini E., Mohammed B. S., Magkos F., Korenblat K. M., Patterson B. W., Klein S., Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 2008 134 2 424 431 2-s2.0-38649111018 10.1053/j.gastro.2007.11.038 (Pubitemid 351173050)
104. Schwarz J. M., Linfoot P., Dare D., Aghajanian K., Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. American Journal of Clinical Nutrition 2003 77 1 43 50 2-s2.0-0037216466 (Pubitemid 36015371)
105. Horton J. D., Goldstein J. L., Brown M. S., SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. Journal of Clinical Investigation 2002 109 9 1125 1131 2-s2.0-0036251153 10.1172/JCI200215593 (Pubitemid 34496588)
106. Polvani S., Tarocchi M., Galli A., PPAR γ and oxidative stress: con(β) catenating NRF2 and FOXO. PPAR Research 2012 2012 15 641087 10.1155/2012/641087
107. Cheung O., Sanyal A. J., Abnormalities of lipid metabolism in nonalcoholic fatty liver disease. Seminars in Liver Disease 2008 28 4 351 359 2-s2.0-56649085036 10.1055/s-0028-1091979
108. Zheng Z., Zhang C., Zhang K., Role of unfolded protein response in lipogenesis. World Journal of Gastroenterology 2010 2 6 203 207
109. Hotamisligil G. S., Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010 140 6 900 917 2-s2.0-77950343252 10.1016/j.cell.2010.02.034
110. Mollica M. P., Lionetti L., Putti R., Cavaliere G., Gaita M., Barletta A., From chronic overfeeding to hepatic injury: role of endoplasmic reticulum stress and inflammation. Nutrition, Metabolism and Cardiovascular Diseases 2011 21 3 222 230 2-s2.0-79951517874 10.1016/j.numecd.2010.10.012
111. Boden G., Duan X., Homko C., Molina E. J., Song W., Perez O., Cheung P., Merali S., Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes 2008 57 9 2438 2444 2-s2.0-52749091008 10.2337/db08-0604
112. Chakrabarti A., Chen A. W., Varner J. D., A review of the mammalian unfolded protein response. Biotechnology and Bioengineering 2011 108 12 2777 2793 2-s2.0-79961161851 10.1002/bit.23282
113. Gething M. J., Role and regulation of the ER chaperone BiP. Seminars in Cell and Developmental Biology 1999 10 5 465 472 2-s2.0-0033208953 10.1006/scdb.1999.0318 (Pubitemid 129513234)
114. Malhi H., Kaufman R. J., Endoplasmic reticulum stress in liver disease. Journal of Hepatology 2011 54 4 795 809 2-s2.0-79952708723 10.1016/j.jhep.2010. 11.005
115. Reznick A. Z., Packer L., Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods in Enzymology 1994 233 357 363 2-s2.0-0028239163 10.1016/S0076-6879(94)33041-7
116. Dean R. T., Gieseg S., Davies M. J., Reactive species and their accumulation on radical-damaged proteins. Trends in Biochemical Sciences 1993 18 11 437 441 2-s2.0-0027482738 10.1016/0968-0004(93)90145-D (Pubitemid 23316629)
117. Stadtman E. R., Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radical Biology and Medicine 1990 9 4 315 325 2-s2.0-0025674536 10.1016/0891-5849(90)90006-5 (Pubitemid 120036900)
118. Gregor M. F., Yang L., Fabbrini E., Mohammed B. S., Eagon J. C., Hotamisligil G. S., Klein S., Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes 2009 58 3 693 700 2-s2.0-62749178966 10.2337/db08-1220
119. Puri P., Mirshahi F., Cheung O., Natarajan R., Maher J. W., Kellum J. M., Sanyal A. J., Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 2008 134 2 568 576 2-s2.0-38649124615 10.1053/j.gastro.2007.10.039 (Pubitemid 351173040)
120. Sharma N. K., Das S. K., Mondal A. K., Hackney O. G., Chu W. S., Kern P. A., Rasouli N., Spencer H. J., Yao-Borengasser A., Elbein S. C., Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects. Journal of Clinical Endocrinology and Metabolism 2008 93 11 4532 4541 2-s2.0-57349110829 10.1210/jc.2008-1001 (Pubitemid 352789557)
121. Appenzeller-Herzog C., Glutathione- and non-glutathione-based oxidant control in the endoplasmic reticulum. Journal of Cell Science 2011 124 part 6 847 855 2-s2.0-79952808113 10.1242/jcs.080895
122. Kim I., Xu W., Reed J. C., Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nature Reviews Drug Discovery 2008 7 12 1013 1030 2-s2.0-57049117856 10.1038/nrd2755
123. Orellana M., Rodrigo R., Varela N., Araya J., Poniachik J., Csendes A., Smok G., Videla L. A., Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients. Hepatology Research 2006 34 1 57 63 2-s2.0-30744476746 10.1016/j.hepres.2005.10.001 (Pubitemid 43091877)
124. Seki S., Kitada T., Sakaguchi H., Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatology Research 2005 33 2 132 134 2-s2.0-29144531843 10.1016/j.hepres.2005.09.020 (Pubitemid 41799790)
125. Chalasani N., Deeg M. A., Crabb D. W., Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. American Journal of Gastroenterology 2004 99 8 1497 1502 2-s2.0-4444382031 10.1111/j.1572-0241.2004.30159.x (Pubitemid 39193189)
126. Yesilova Z., Yaman H., Oktenli C., Ozcan A., Uygun A., Cakir E., Sanisoglu S. Y., Erdil A., Ates Y., Aslan M., Musabak U., Erbil M. K., Karaeren N., Dagalp K., Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. American Journal of Gastroenterology 2005 100 4 850 855 2-s2.0-20244370723 10.1111/j.1572-0241.2005. 41500.x (Pubitemid 40592378)
127. Konishi M., Iwasa M., Araki J., Kobayashi Y., Katsuki A., Sumida Y., Nakagawa N., Kojima Y., Watanabe S., Adachi Y., Kaito M., Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane. Journal of Gastroenterology and Hepatology 2006 21 12 1821 1825 2-s2.0-33750097483 10.1111/j.1440-1746.2006.04420.x (Pubitemid 44657003)
128. Robertson G., Leclercq I., Farrell G. C., Nonalcoholic Steatosis and Steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. American Journal of Physiology 2001 281 5 G1135 G1139 2-s2.0-0035196704
129. Pérez-Carreras M., Del Hoyo P., Martín M. A., Rubio J. C., Martín A., Castellano G., Colina F., Arenas J., Solis-Herruzo J. A., Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003 38 4 999 1007 2-s2.0-18144444592 10.1053/jhep.2003.50398 (Pubitemid 37221683)
130. Cortez-Pinto H., Chatham J., Chacko V. P., Arnold C., Rashid A., Diehl A. M., Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. Journal of the American Medical Association 1999 282 17 1659 1664 2-s2.0-0033520771 10.1001/jama.282.17.1659 (Pubitemid 29513973)
131. Videla L. A., Tapia G., Rodrigo R., Pettinelli P., Haim D., Santibãez C., Araya A. V., Smok G., Csendes A., Gutierrez L., Rojas J., Castillo J., Korn O., Maluenda F., Díaz J. C., Rencoret G., Poniachik J., Liver NF- B and AP-1 DNA binding in obese patients. Obesity 2009 17 5 973 979 2-s2.0-67349085771 10.1038/oby.2008.601
132. Ribeiro P. S., Cortez-Pinto H., Solá S., Castro R. E., Ramalho R. M., Baptista A., Moura M. C., Camilo M. E., Rodrigues C. M. P., Hepatocyte apoptosis, expression of death receptors, and activation of NF- B in the liver of nonalcoholic and alcoholic steatohepatitis patients. American Journal of Gastroenterology 2004 99 9 1708 1717 2-s2.0-4544335155 10.1111/j.1572-0241.2004. 40009.x (Pubitemid 39237497)
133. Gloire G., Legrand-Poels S., Piette J., NF- B activation by reactive oxygen species: fifteen years later. Biochemical Pharmacology 2006 72 11 1493 1505 2-s2.0-33750523632 10.1016/j.bcp.2006.04.011 (Pubitemid 44666727)
134. Naugler W. E., Karin M., NF- B and cancer-identifying targets and mechanisms. Current Opinion in Genetics and Development 2008 18 1 19 26 2-s2.0-43749098070 10.1016/j.gde.2008.01.020 (Pubitemid 351694451)
135. Kamata H., Honda S. I., Maeda S., Chang L., Hirata H., Karin M., Reactive oxygen species promote TNF α -induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005 120 5 649 661 2-s2.0-14844327760 10.1016/j.cell.2004.12.041 (Pubitemid 40343077)
136. Videla L. A., Liver NF- B and AP-1 activation and PPAR- α expression are negatively correlated in obese patients: pro-inflammatory implications. Clinical Nutrition 2010 29 5 687 688 2-s2.0-77957362125 10.1016/j.clnu.2010.03.006
137. Wigg A. J., Roberts-Thomson I. C., Dymock R. B., McCarthy P. J., Grose R. H., Cummins A. G., The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001 48 2 206 211 2-s2.0-0035125052 10.1136/gut.48.2.206 (Pubitemid 32141844)
138. Crespo J., Cayoen A., Fernendez-Gil P., Hernndez-Guerra M., Mayorga M., Domnguez-Dez A., Fernndez-Escalante J. C., Pons-Romero F., Gene expression of tumor necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001 34 6 1158 1163 2-s2.0-0035183475 10.1053/jhep.2001.29628 (Pubitemid 33096588)
139. Hui J. M., Hodge A., Farrell G. C., Kench J. G., Kriketos A., George J., Beyond insulin resistance in NASH: TNF- α or adiponectin? Hepatology 2004 40 1 46 54 2-s2.0-3042744737 10.1002/hep.20280 (Pubitemid 38868922)
140. Guerra Ruiz A., Casafont F., Crespo J., Cayón A., Mayorga M., Estebanez A., Fernadez-Escalante J. C., Pons-Romero F., Lipopolysaccharide- binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obesity Surgery 2007 17 10 1374 1380 2-s2.0-38449120093 10.1007/s11695-007-9243-7
141. Schwabe R. F., Seki E., Brenner D. A., Toll-like receptor signaling in the liver. Gastroenterology 2006 130 6 1886 1900 2-s2.0-33646347356 10.1053/j.gastro.2006.01.038 (Pubitemid 43668871)
142. Hayden M. S., Ghosh S., Signaling to NF- B. Genes and Development 2004 18 18 2195 2224 2-s2.0-4444376712 10.1101/gad.1228704 (Pubitemid 39209568)
143. Gentile C. L., Frye M. A., Pagliassotti M. J., Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease. BioFactors 2011 37 1 8 16 2-s2.0-79951600838 10.1002/biof.135
144. Capanni M., Calella F., Biagini M. R., Genise S., Raimondi L., Bedogni G., Svegliati-Baroni G., Sofi F., Milani S., Abbate R., Surrenti C., Casini A., Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Alimentary Pharmacology and Therapeutics 2006 23 8 1143 1151 2-s2.0-33646882162 10.1111/j.1365-2036.2006.02885.x (Pubitemid 43779354)
145. Spadaro L., Magliocco O., Spampinato D., Piro S., Oliveri C., Alagona C., Papa G., Rabuazzo A. M., Purrello F., Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Digestive and Liver Disease 2008 40 3 194 199 2-s2.0-38749115791 10.1016/j.dld.2007.10.003 (Pubitemid 351181793)
146. Zhu F. S., Liu S., Chen X. M., Huang Z. G., Zhang D. W., Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World Journal of Gastroenterology 2008 14 41 6395 6400 2-s2.0-63449137594 10.3748/wjg.14.6395
147. Hatzitolios A., Savopoulos C., Lazaraki G., Sidiropoulos I., Haritanti P., Lefkopoulos A., Karagiannopoulou G., Tzioufa V., Dimitrios K., Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian Journal of Gastroenterology 2004 23 4 131 134 2-s2.0-4344593276 (Pubitemid 39145721)
148. Tanaka N., Sano K., Horiuchi A., Tanaka E., Kiyosawa K., Aoyama T., Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. Journal of Clinical Gastroenterology 2008 42 4 413 418 2-s2.0-41349102802 10.1097/MCG.0b013e31815591aa (Pubitemid 351450629)
149. Parker H. M., Johnson N. A., Burdon C. A., Cohn J. S., O'Connor H. T., George J., Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic and meta-analysis. Journal of Hepatology 2012 56 4 944 951
150. Jump D. B., N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Current Opinion in Lipidology 2008 19 3 242 247 2-s2.0-43249114663 10.1097/MOL.0b013e3282ffaf6a (Pubitemid 351653561)
151. De Roos B., Mavrommatis Y., Brouwer I. A., Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease. British Journal of Pharmacology 2009 158 2 413 428 2-s2.0-69549107757 10.1111/j.1476-5381.2009.00189.x
152. Shapiro H., Tehilla M., Attal-Singer J., Bruck R., Luzzatti R., Singer P., The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clinical Nutrition 2011 30 1 6 19 2-s2.0-79451476075 10.1016/j.clnu.2010.06.001